The phosphoinositide 3-kinase (PI3K) pathway is a crucial signal transduction system linking the activation of receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs) and oncogenes ...

Table 1: Kinase Activity and Ligand Binding Capability ... Ullrich, A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nature Reviews Cancer 4, 361–370 (2004) doi:10. ...

Using inhibitor and conditional knockout approaches, scientists led by Nancy Ip of the Hong Kong University of Science and Technology found that expression of EphA4, a receptor tyrosine kinase and AD ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) being jointly developed and commercialized by AstraZeneca and HUTCHMED. In 2023, savolitinib and TAGRISSO ® ...

The Falke group is currently investigating the molecular mechanisms of on-off switching of components within the chemosensory array, especially the mechanisms by which transmembrane receptors bind ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...